Full Text View
Tabular View
No Study Results Posted
Related Studies
Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
This study is ongoing, but not recruiting participants.
Study NCT00555581   Information provided by Hospital for Special Surgery, New York

First Received on November 7, 2007.   Last Updated on January 31, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Sclerosis
Additional conditions recognized in this trial
Scleroderma, Diffuse
Scleroderma, Systemic
Sclerosis
More general conditions related to this trial
Connective Tissue Diseases
Pathologic Processes
Skin Diseases
Interventions listed in this trial
Imatinib Mesylate
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Hospital for Special Surgery, New York
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services